在I类和II类修复中,两种离子释放散装复合材料的临床性能:为期两年的评估
Eman H Albelasy1,2, Hamdi H Hamama1,3, Hooi Pin Chew2
1Conservative Dentistry Department, Faculty of Dentistry, Mansoura University, Mansoura, Aldakhlia, Egypt.
概括
离子释放散装填充复合材料在I和II类腔中表现出与常规散装填充树脂复合材料相比的2年临床性能,这表明它们的使用有希望的证据.
科学领域:
- 恢复性牙科 恢复性牙科
- 牙科材料科学 牙科材料科学
背景情况:
- 大量填充复合材料在牙科修复中提供了效率.
- 离子释放牙科材料旨在提供超出机械修复的治疗效益.
研究的目的:
- 为了比较两种离子释放散装填充复合材料 (Cention N和Surefil One) 与常规散装填充树脂复合材料 (Powerfil) 的两年临床性能.
- 为了评估离子释放材料在I和II类空腔中的有效性.
主要方法:
- 一项随机临床试验涉及32名患者,其中96名患者使用Cention N,Surefil One或Powerfil进行了修复.
- 临床评估是在基线,6个月,1年,2年使用外国直接投资标准进行的.
- 统计分析包括克鲁斯卡尔-瓦利斯,弗里德曼,曼-惠特尼和威尔科克森等级测试.
主要成果:
- 总体而言,临床成功率很高:Powerfil100%;Surefil One100%;Cention N在2年后96.3%.
- 与树脂复合材料相比,Cention N在2年后显示了边际完整性在统计学上显著下降.
- 在任何一项修复中都没有观察到任何复发性衰变.
结论:
- 两种离子释放散装填充复合材料 (Cention N和Surefil One) 在两年内表现出可接受的临床性能,与传统散装填充树脂复合材料 (Powerfil) 相比.
- 这些发现提供了有希望的证据,支持在I和II类修复中临床使用离子释放复合材料.
更多相关视频
05:30Roughness Impact of Piezoelectric Dental Scaler on Two Distinct Flowable Composite Filling Materials
Published on: January 10, 2025
630
07:42Quasistatic Mechanical Testing for Computer-Aided Design and Manufacturing Occlusal Veneers Cemented to Milled Dentin Analog Material
Published on: December 20, 2024
405
相关概念视频
Retarders
Retarders are chemical admixtures designed to extend the setting time, which is especially useful when there is a delay in sequential concrete pours to prevent cold joints and to achieve a cohesive structure. Retarders, when used in appropriate amounts, can also enhance the architectural appearance of exposed aggregate finishes.
The function of retarders is to delay the setting of concrete, and this effect can be measured using a penetration test. The retardation process involves adding...
The function of retarders is to delay the setting of concrete, and this effect can be measured using a penetration test. The retardation process involves adding...
Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
